Volume : 08, Issue : 10, October – 2021

Title:

29.DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF POSACONAZOLE IN API AND TABLET FORMULATION

Authors :

Gurumurthy.Telugu* Dr.P. Venkata Suresh

Abstract :

The objective of the present work is Method Development and Validation for the estimation of Posaconazole in Bulk and Formulation by RP-HPLC. A simple, rapid, accurate, precise, robust and reproducible RP-HPLC method was developed for the estimation of Posaconazole. The method was developed by using Inertsil ODS-2V column, with Mobile phase comprising of ACN: Water in the ratio of (90:10v/v) at a flow rate of 1ml/min and the effluents were monitored at 262nm using PDA detector. Chromatograms are eluted at retention time of 3.98min The R2 was found to be 0.9998. The accuracy was carried out and results were within 98-102% and the %Relative Standard Deviation was found to be ˂2%. Detection Limit and Quantitation Limit were found to be 0.26µg/ml and 0.80µg/ml respectively. The proposed method was successfully applied to posaconazole bulk quantification, showing the method is useful for determination of the drug in routine analysis
Keywords: Simple, RP-HPLC, Chromatographic separation, Posaconazole, ICH guidelines,

Cite This Article:

.Please cite this article in press Gurumurthy.Telugu et al, Development And Validation Of RP-HPLC Method for The Estimation of Posaconazole in API and Tablet Formulation ., Indo Am. J. P. Sci, 2021; 08(10).

Number of Downloads : 10

References:

1. https://en.wikipedia.org/wiki/Posaconazole
2. . 3. https://pubchem.ncbi.nlm.nih.gov/compound/Posaconazole
3. ICH guidelines, pharmaceutical development: Q8, (R2). 2009.
4. O. A. Cornely, J. Maertens, D. J. Winston et al., “Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia,” The New England Journal of Medicine, vol. 356, no. 4, pp. 348–359, 2007.
5. D. A. Hamdy, S. El-Salem, H. El-Geed, and M. Zaidan, “Posaconazole, a prophylactic therapy in patients with haematological cancer: drug use evaluation study,” European Journal of Hospital Pharmacy, vol. 20, pp. 223–226, 2013.
6. S. Chhun, E. Rey, A. Tran, O. Lortholary, G. Pons, and V. Jullien, “Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection,” Journal of Chromatography B, vol. 852, pp. 223–228, 2007
7. D. Storzinger, S. Swoboda, C. Lichtenstern, C. Muller, M. A. Weigand, and T. Hoppe-Tichy, “Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction,” Clinical Chemistry and Laboratory Medicine, vol. 46, no. 12, pp. 1747–1751, 2008.
8. D. A. Hamdy and D. R. Brocks, “A stereospecific high-performance liquid chromatographic assay for the determination of ketoconazole enantiomers in rat plasma,” Biomedical Chromatography, vol. 22, pp. 542–547, 2008.
9. J. M. Cunliffe, C. F. Noren, R. N. Hayes, R. P. Clement, and J. X. Shen, “A high-throughput LC-MS/MS method for the quantitation of posaconazole in human plasma: implementing fused core silica liquid chromatography,” Journal of Pharmaceutical and Biomedical Analysis, vol. 50, no. 1, pp. 46–52, 2009
10. L. Franceschi, S. D’Aronco, and M. Furlanut, “Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of voriconazole and posaconazole in serum samples from patients with invasive mycoses,” Journal of Bioanalysis and Biomedicine, vol. 3, pp. 92–97, 2011.
11. B. Rochat, A. Pascual, B. Pesse et al., “Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing,” Antimicrobial Agents and Chemotherapy, vol. 54, pp. 5074–5081, 2010.
12. . Thimmaraju, MK., Pamulaparthy, V., and Raghunandan, N., Development and validation of RP-HPLC method for the determination of itraconazole in bulk and capsule dosage form. Journal of Analytical Chemistry, 2012. 2: 10